A recent study (SQ Hutsell, M Wu, KT Park. JPGN 2017; 65: 430-31) examined two practice changes with regard to infliximab (IFX) infusions:
- 1-hour infusions
- Omission of premedications
The authors reviewed ~900 IFX infusions; though, only 111 infusions were administered without premedications. These two changes resulted in a 51% decrease in infusion hours, despite a 9% increase in total number infusions. No increase in adverse reactions was identified.
The authors state that these changes improve patient experience, shorten monitoring time, and reduce costs.